Nordion Inc (NDZ) 12.99 $NDZ
Sterilization Technologies - A 2015 Global Market Overview of the $9.5 Billion Market
M2 - Wed Jan 21, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/4j5x5l/sterilization) has announced the addition of the "Sterilization Technologies - A Global Market Overview" report to their offering. Global sterilization market is expected to touch US$5.3 billion 2015 and projected to touch US$9.5 billion in 2020, growing by a CAGR of 12% between 2014 and 2020. Filtration estimated the leading technology for sterilization in 2014 with US$2.7 billion and expected to touch US$3.1 billion 2015 while Medical Devices is the largest application area with market worth US$3 billion in 2014. Growing and aging global population has led to more and more surgeries being performed today than ever before. Therefore, maintaining patient safety assumes extreme criticality in the field of surgery and rules and regulations have to be in place for every aspect of the process for ensuring that errors are averted at all costs. As a consequence, disinfection and sterilization of surgical instruments becomes one area of crucial significance for upholding patient safety. This factor has a direct correlation with an increase in demand for sterilization equipment. Given the fact that every hospital and healthcare facility gives paramount importance to patient safety, sterilization techniques are most widely utilized for medical device applications. This report reviews, analyses and projects the Sterilization technologies market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. Global market for sterilization technologies is projected to touch $9.5 billion by 2020 growing at a decent rate compounded annually at 12% for the period 2014-2020. The United States leads the global market with a share of 29% closely followed by Europe with 27%, during 2014-2020, converting to US$1.4 billion and 1.3 billion respectively in 2014. Worldwide market for sterilization technologies explored in this study includes Chemical Sterilization, Heat Sterilization, Filtration Sterilization and Radiation Sterilization. The report also analyzes the market by application comprising Medical Devices, Pharmaceuticals, Life Sciences and Others. The global market for the above mentioned technologies and applications is analyzed in terms of USD. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Sterilization Applications - A Snapshot 3. Key Market Trends 4. Key Global Players 5. Key Business Trends 6. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. The United States 2. Europe 3. Asia-Pacific 4. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part
Annexure 1. Research Methodology 2. Feedback Executive Summary: - 3M Company - Advanced Sterilization Products - Andersen Products, Inc. - Baumer SA - Belimed AG - Cantel Medical Corp. - Getinge AB - Medline Industries, Inc - Nordion, Inc. - Sakura Seiki Co Ltd - Sterigenics International Inc. - Sterile Technologies, Inc. - Steris Corporation - Synergy Health Plc - TSO3 Inc. - Tuttnauer USA Co Ltd For more information visit http://www.researchandmarkets.com/research/4j...rilization
MMM: 165.94 (+0.03), NDZ: 12.99 (-0.01), CMN: 44.28 (+1.09)
Global Nuclear Medicine/Radiopharmaceuticals Market Forecast 2014-2020
M2 - Wed Jan 07, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/n6gz6w/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2020" report to their offering. The global nuclear medicine/radiopharmaceutical market is poised to reach around $6 billion by 2017 at a CAGR of more than 7%. The largest share in the global radiopharmaceuticals market is accounted by North America. Besides U.S. market Asia-Pacific region is also poised to show a remarkable growth. The Asia-Pacific radiopharmaceutical market is poised to reach approximately 14% by 2017 at a CAGR of around 11%. Countries such as China, India, Japan, South Korea, Brazil and South Africa possess reactors and other production units for isotopes. Moreover, the government initiative in funding the isotope manufacturers is also expected to boost the market growth. The global nuclear medicine/radiopharmaceutical market is majorly comprised of five key players accounting for around 50% of the total market share. Key players include Covidien (), IBA Group, Lantheus Medical Imaging, Nordion, Triad Isotopes, Siemens Healthcare (PETNET Solutions), and NTP Radioisotopes. Acquisitions and mergers, new product launch, agreements and collaborations, and expansions were the main strategies followed by the key players in the global nuclear medicine market. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Global Nuclear Medicine Market By End-Users 5. Radiopharmaceuticals By Type 6. Stable Isotopes 7. Regional Market Analysis 8. Company Developments 9. Major Player Profiles - CIL - Cardinal Health, Inc. - GE Healthcare - IBA Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Mallinckrodt Plc - NTP Radioisotopes - Nordion Inc - Taiyo Nippon Sanso Corporation For more information visit http://www.researchandmarkets.com/research/n6gz6w/nuclear
CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020
M2 - Mon Nov 17, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/llklcc/global) has announced the addition of the "Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020" report to their offering. The nuclear medicine market by indication is segmented as oncology, cardiology, inflammation, nephrology, neurology, lymphology, thyroid glands, and gastro intestinal. Cardiology holds the largest share in 2013 in SPECT nuclear medicine market whereas nephrology is the fastest growing application of this segment. Increasing incidence of cardiac ailments, aging population, and preference for non invasive diagnostic procedures are driving the market for cardiology segment. Oncology contributes to the largest share of around $1 billion and is also the fastest growing segment in PET market with a CAGR of more than 7%. Nephrology is the fastest growing segment in the therapeutics. Increase in therapeutic application, public awareness, use of hybrid imaging, technological advancements, cyclotron production of radiopharmaceuticals, efficient diagnosis and treatments, emerging radioisotopes and replacement of traditional equipment are factors or opportunities expected to drive the nuclear medicine market. However, stringent regulatory issues, supply shortage, radio toxicity, high cost and huge investment are factors hindering the market growth during the forecasted period. North America holds the largest share for nuclear medicine market, followed by Europe. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. Asia-Pacific (APAC) and Rest of the World are poised to grow at a CAGR of more than 6% and 8% respectively by 2020. This region growth is attributed to aging population, rise in public awareness. Countries like China, India, Australia, and Brazil will be major contributors to the growth of the market. Reasons to Buy: - Nuclear medicine/Radiopharmaceuticals usage and demand by various end-users across the globe - Emerging isotopes as well as alternative isotopes for use both in the SPECT and PET segments - Emerging applications in Nuclear Medicine - Regulations and Reimbursement scenario - Stable isotopes study being a value addition - Competitive landscaping and Major player profiles Key Topics Covered: 1. Summary 2. Introduction 3. Market Overview 4. Global Radiopharmaceutical market, by End-User 5. Global Radiopharmaceutical market, by Application 6. Stable Isotopes 7. Geographic Analysis 8. Competitors Landscape 9. Major Company Profiles - CIL - Cardinal Health, Inc. - GE Healthcare - IBA Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Mallinckrodt Plc - NTP Radioisotopes - Nordion Inc - Taiyo Nippon Sanso Corporation For more information visit http://www.researchandmarkets.com/research/llklcc/global
CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Global Nuclear Medicine/Radiopharmaceuticals Global Market 2014-2020
M2 - Mon Sep 22, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jr579/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2020" report to their offering. The global nuclear medicine/radiopharmaceutical market is poised to reach around $6 billion by 2017 Nuclear medicine deals with the radioisotope applications in diagnosis and treatment of disease. Radiopharmaceuticals are drugs containing radionuclide's. Administration of radiopharmaceuticals facilitated to image bone, organs and the disease process in body at early stage based on cellular function and physiology. Around 200 radioisotopes are used regularly by the physicians for diagnosis and treatment across the globe. The global nuclear medicine/radiopharmaceutical market is segmented into diagnostic (SPECT and PET) and therapeutic areas (Beta, Alpha emitter, and Brachytherapy). Tc-99m and F-18 are proved to be the most dominant isotopes in SPECT and PET markets respectively. In addition, Rb-82 and Tl-201 are expected to register high growth in diagnostic market. Whereas Y-90 and Lu-177 are witnessing high growths in beta therapy radioisotopes market. Paediatrics, cardiology, oncology, neurology and psychiatry are some of the prominent applications areas of nuclear medicine. Increase in use of SPECT and PET scans, and awareness by physicians for treatment of coronary heart disease, Alzheimer's disease, breast cancer and bone metastasis are some of the major drivers of nuclear medicine market. Moreover, the growing therapeutic areas such as lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma also play a crucial role in the market growth. Whereas, the half-life of radiopharmaceuticals, high capital demand, lack of proper GMP (Good Manufacturing Practice), and inefficient effluent treatment are found to be the major factors hampering the nuclear medicine/radiopharmaceutical market growth. Increasing medical applications, rising demand in emerging economies and technological advancements in neurological applications are providing growth opportunities while, stringent regulatory guidelines and shutdown of nuclear reactors for radioisotope production are considered to be the major threats to the market growth. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Global Nuclear Medicine Market By End-Users 5. Radiopharmaceuticals By Type 6. Stable Isotopes 7. Regional Market Analysis 8. Company Developments 9. Major Player Profiles - CIL - Cardinal Health, Inc. - GE Healthcare - IBA Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Mallinckrodt Plc - NTP Radioisotopes - Nordion Inc - Taiyo Nippon Sanso Corporation For more information visit http://www.researchandmarkets.com/research/4jr579/nuclear
CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Asia-Pacific Nuclear Medicine Market - Trends And Forecasts 2014-2020
M2 - Thu Sep 18, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hvtnrb/asiapacific) has announced the addition of the "Asia-Pacific Nuclear Medicine Market - Trends And Forecasts (2014-2020)" report to their offering. Asia-pacific nuclear medicine market was valued at $480.5 million in 2012 and is expected to reach $853 million in 2019 with a healthy CAGR of 10.6% One of the popular forms of medical specialty, nuclear medicines involves application of radioactive substances in treatment of various diseases and disorders. Also known as, radiopharmaceuticals, these drugs contain radio-emitting ionization radiation and help in diagnosing disease and provide suitable treatment. Accurate identification and treatment of the disease are two major advantage of the nuclear medicine. Rising demand and evolving technology in the healthcare industry are the strongest driving factors for the global nuclear medicine market, which is aiming at steady growth in terms of revenue and global adoption. Increasing use of SPECT and PET technology for the treatment of the diseases propels market to grow further. Persistent side effects of cancer chemotherapy and radiation therapy are also the driving factors for the market. However, market is constrained by short half life of the radioisotopes which make them difficult to use. Asia-Pacific nuclear medicine market is segmented by Therapeutic market and Diagnostic market. Both these segments are further categorized based on the types of medicines, their applications and demands. Based on these segments, experts claim that the therapeutic market is mainly dominated by beta emitters for oncology applications. Diagnostic market on the other hand is dominated by radioisotopes such as SPECT and PET . Based on countries, market is segmented into India, China and Japan. Japan is the dominant market for diagnostic radioisotopes with almost 40% share and has around 1,600 gamma cameras. The total number of PET institutes in Japan has increased around 6-7 times in the last 10 years. Major players in the market are Covidien , IBA Group, Lantheus Medical Imaging, Triad Isotopes, Siemens Healthcare (PETNET Solutions), NTP Radioisotopes. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Market Dynamics 5. Asia-Pacific Nuclear Medicine Market Segmentation 6. Nuclear Medicine Market, By Type Of Products 7. Diagnostic Market, By Applications 8. Others 9. Competitive Landscape 10. Top Players In The Market Companies Featured: - Bracco Imaging S.P.A. - Cambridge Isotope Laboratories, Inc. - Cardinal Health, Inc - Covidien, Plc - Eczacibasi-Monrol - Fujifilm Holdings Corporation - GE Healthcare (Subsidiary Of General Electric Company) - Iba Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Nordion, Inc. For more information visit http://www.researchandmarkets.com/research/hv...siapacific
GE: 25.15 (+0.26), CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Europe Nuclear Medicine Market - Trends And Forecasts 2014-2020
M2 - Wed Sep 17, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkxb7b/europe_nuclear) has announced the addition of the "Europe Nuclear Medicine Market - Trends And Forecasts (2014-2020)" report to their offering. Europe market for nuclear medicine stood at $1.4 billion in 2014 and is expected to reach approximately $1.9 billion in 2019 with a CAGR of 7.2% Market for Technetium-99m is expected to increase owing to the rise in cases of cancer and cardiac ailments. Nuclear medicine has high potential for treatment of neurological diseases like Parkinson's, Alzheimer's and dementia. Practitioners prefer radiopharmaceuticals over conventional methods of treatments in neurological diseases. Study estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Market Dynamics 5. Europe Nuclear Medicine Market Segmentation 6. Nuclear Medicine Market, By Type Of Products 7. Diagnostic Market, By Application 8. Others 9. Competitive Landscape 10. Company Profiles - Bracco Imaging S.P.A. - Cambridge Isotope Laboratories, Inc. - Cardinal Health, Inc. - Covidien, Plc - Eczacibasi-Monrol - Fujifilm Holdings Corporation - Ge Healthcare (Subsidiary Of General Electric Company) - Iba Group - Institute Of Radioelement (IRE) - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Nordion, Inc. For more information visit http://www.researchandmarkets.com/research/vk...pe_nuclear
GE: 25.15 (+0.26), CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Global Nuclear Medicine Market - Growth, Trends & Forecasts 2014-2019
M2 - Tue Sep 09, 8:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9krpdg/global_nuclear) has announced the addition of the "Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019)" report to their offering. Nuclear medicine market is estimated to reach US$1.69 Billion by 2015 Radiopharmaceuticals/ Nuclear are drugs that contain radionuclide-emitting ionization radiation, used in the nuclear imaging field to diagnose and treat diseases. Increasing incidences of cancer and cardiac ailments, Increasing awareness for radiopharmaceuticals, and ready availability of radiopharmaceuticals are the major driving forces for this market. Furthermore, increased public awareness and use of SPECT and PET also fuels the market growth. Growth in this market will be driven by new technology and varied uses of the technology. The major constrains for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Global Markets: Segmentation By Diagnostics 5. Global Markets: Segmentation By Therapeutics 6. Global Markets: Segmentation By Application 7. Global Markets:Segmentation By Geography 8. Competitive Landscape 9. Top Players In The Market 10. Company Profiles - Australian Nuclear Association And Technology Organization (Ansto) - Board Of Radiation And Isotope Technology (Brit) - Bracco Imaging S.P.A. - Cambridge Isotope Laboratories, Inc. - Cardinal Health, Inc. - Covidien, Plc - Eczacibasi-Monrol - Fujifilm Holdings Corporation - Ge Healthcare (Subsidiary Of General Electric Company) - Iba Group - Institute Of Atomic Energy Polatom Radioisotope Centre - Institute Of Isotopes Co., Ltd. - Institute Of Radioelement (IRE) - Institutes - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Nordion, Inc. - Ntp Radioisotopes (PTY), Ltd. - Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.) - Rotem Industries, Ltd., Inc. - Taiyo Nippon Sanso Corporation - Urenco Limited For more information visit http://www.researchandmarkets.com/research/9k...al_nuclear
GE: 25.15 (+0.26), CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Nordion's outstanding common shares acquired by Sterigenics International
M2 - Thu Aug 07, 7:18AM CDT
Nordion (TSX:NDN.TO) (NYSE:NDZ) revealed on Wednesday that it has acquired all of the outstanding common shares of Nordion by an affiliate of Sterigenics International under a plan of arrangement.
NDZ: 12.99 (-0.01)
Sterigenics International Completes $826 Million Acquisition of Nordion Inc.
Business Wire - Wed Aug 06, 1:01PM CDT
Sterigenics International LLC, the leading global provider of outsourced contract sterilization services and a portfolio company of GTCR, today announced it has completed its $826 million acquisition of Nordion Inc. (TSX:NDN) (NYSE:NDZ).
NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01)
Nordion Announces Completion of Acquisition by Sterigenics International
Business Wire - Wed Aug 06, 12:56PM CDT
Nordion Inc. (TSX:NDN) (NYSE:NDZ), a leading provider of products and services to the global health science market, announced today the successful completion of the previously announced plan of arrangement (the "Arrangement"
and all of the outstanding common shares of Nordion have been acquired by an affiliate of Sterigenics International LLC ("Sterigenics" . Pursuant to the Arrangement, the former holders of Nordion common shares will receive US$13.00 in cash in exchange for each common share held.
NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01)
NYSE stocks posting largest volume decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
BRT: 6.98 (-0.02), MOG.B: 74.29 (+1.81), MOG.A: 74.61 (+1.47), FCE.A: 25.32 (-0.08), STZ: 113.03 (-0.48), NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01), BOXC: 23.30 (-0.53), STZ.B: 112.58 (-0.82)
Nordion Receives Investment Canada Act Approval and Announces Expected Closing Date for Acquisition by Sterigenics
Business Wire - Fri Aug 01, 4:00PM CDT
Nordion Inc. (TSX:NDN) (NYSE:NDZ) announced today that the Minister of Industry has approved the previously announced proposed acquisition of all the common shares of Nordion Inc. by Sterigenics, pursuant to the terms of the Investment Canada Act. This approval was the last regulatory approval required for the proposed acquisition.
NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01)
Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2019
M2 - Mon Jul 21, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx9c82/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2019" report to their offering. The global nuclear medicine/radiopharmaceutical market is poised to reach around $6 billion by 2017 at a CAGR of more than 7% The largest share in the global radiopharmaceuticals market is accounted by North America. Besides U.S. market Asia-Pacific region is also poised to show a remarkable growth. The Asia-Pacific radiopharmaceutical market is poised to reach approximately 14% by 2017 at a CAGR of around 11%. Countries such as China, India, Japan, South Korea, Brazil and South Africa possess reactors and other production units for isotopes. Moreover, the government initiative in funding the isotope manufacturers is also expected to boost the market growth. The global nuclear medicine/radiopharmaceutical market is majorly comprised of five key players accounting for around 50% of the total market share. Key players include Covidien (), IBA Group, Lantheus Medical Imaging, Nordion, Triad Isotopes, Siemens Healthcare (PETNET Solutions), and NTP Radioisotopes. Acquisitions and mergers, new product launch, agreements and collaborations, and expansions were the main strategies followed by the key players in the global nuclear medicine market. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Global Radiopharmaceutical market, by End-User 5. Global Radiopharmaceutical market, by Application 6. Stable Isotopes 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - CIL - Cardinal Health, Inc. - GE Healthcare - IBA Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Mallinckrodt Plc - NTP Radioisotopes - Nordion Inc - Taiyo Nippon Sanso Corporation For more information visit http://www.researchandmarkets.com/research/wx9c82/nuclear
CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Nordion announces waiting period under HSR Act terminated for proposed acquisition by Sterigenics
M2 - Mon Jul 14, 6:12AM CDT
Health science company Nordion Inc (TSX:NDN) (NYSE:NDZ) announced on Friday the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act0, as amended, on 10 July 2014 by the Federal Trade Commission with respect to Sterigenics' proposed acquisition of Nordion.
NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01)
Lorillard and Fastenal are big market movers
AP - Fri Jul 11, 3:59PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
ZUMZ: 38.84 (+0.14), RAI: 71.86 (-1.23), AMZN: 381.83 (+4.66), LO: 67.30 (-0.80), CRAY: 32.65 (+0.24), UAL: 66.23 (-1.11), RCII: 30.49 (+0.92), FAST: 42.50 (+0.26), AMRE: 26.51 (unch), EBAY: 56.47 (+1.73), ECOM: 9.69 (+0.63), SRPT: 12.76 (+0.11), REG: 66.77 (-0.46), NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01), CBS.A: 60.82 (+1.76), MTG: 9.18 (+0.07), CBS: 59.83 (+2.06)
NYSE stocks posting largest percentage increases
AP - Fri Jul 11, 12:38PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at 1 p.m.:
FSM: 4.56 (+0.03), FVI.TO: 5.67 (+0.02), EDR.TO: 3.08 (+0.10), TCI: 10.67 (-0.13), GPRK: 4.35 (+0.17), ECOM: 9.69 (+0.63), LO: 67.30 (-0.80), HGT: 8.10 (+0.02), NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01), EXK: 2.48 (+0.08)
Sterilization Technologies - A 2015 Global Market Overview of the $9.5 Billion Market
M2 - Wed Jan 21, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/4j5x5l/sterilization) has announced the addition of the "Sterilization Technologies - A Global Market Overview" report to their offering. Global sterilization market is expected to touch US$5.3 billion 2015 and projected to touch US$9.5 billion in 2020, growing by a CAGR of 12% between 2014 and 2020. Filtration estimated the leading technology for sterilization in 2014 with US$2.7 billion and expected to touch US$3.1 billion 2015 while Medical Devices is the largest application area with market worth US$3 billion in 2014. Growing and aging global population has led to more and more surgeries being performed today than ever before. Therefore, maintaining patient safety assumes extreme criticality in the field of surgery and rules and regulations have to be in place for every aspect of the process for ensuring that errors are averted at all costs. As a consequence, disinfection and sterilization of surgical instruments becomes one area of crucial significance for upholding patient safety. This factor has a direct correlation with an increase in demand for sterilization equipment. Given the fact that every hospital and healthcare facility gives paramount importance to patient safety, sterilization techniques are most widely utilized for medical device applications. This report reviews, analyses and projects the Sterilization technologies market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. Global market for sterilization technologies is projected to touch $9.5 billion by 2020 growing at a decent rate compounded annually at 12% for the period 2014-2020. The United States leads the global market with a share of 29% closely followed by Europe with 27%, during 2014-2020, converting to US$1.4 billion and 1.3 billion respectively in 2014. Worldwide market for sterilization technologies explored in this study includes Chemical Sterilization, Heat Sterilization, Filtration Sterilization and Radiation Sterilization. The report also analyzes the market by application comprising Medical Devices, Pharmaceuticals, Life Sciences and Others. The global market for the above mentioned technologies and applications is analyzed in terms of USD. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Sterilization Applications - A Snapshot 3. Key Market Trends 4. Key Global Players 5. Key Business Trends 6. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. The United States 2. Europe 3. Asia-Pacific 4. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part
Annexure 1. Research Methodology 2. Feedback Executive Summary: - 3M Company - Advanced Sterilization Products - Andersen Products, Inc. - Baumer SA - Belimed AG - Cantel Medical Corp. - Getinge AB - Medline Industries, Inc - Nordion, Inc. - Sakura Seiki Co Ltd - Sterigenics International Inc. - Sterile Technologies, Inc. - Steris Corporation - Synergy Health Plc - TSO3 Inc. - Tuttnauer USA Co Ltd For more information visit http://www.researchandmarkets.com/research/4j...rilization MMM: 165.94 (+0.03), NDZ: 12.99 (-0.01), CMN: 44.28 (+1.09)
Global Nuclear Medicine/Radiopharmaceuticals Market Forecast 2014-2020
M2 - Wed Jan 07, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/n6gz6w/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2020" report to their offering. The global nuclear medicine/radiopharmaceutical market is poised to reach around $6 billion by 2017 at a CAGR of more than 7%. The largest share in the global radiopharmaceuticals market is accounted by North America. Besides U.S. market Asia-Pacific region is also poised to show a remarkable growth. The Asia-Pacific radiopharmaceutical market is poised to reach approximately 14% by 2017 at a CAGR of around 11%. Countries such as China, India, Japan, South Korea, Brazil and South Africa possess reactors and other production units for isotopes. Moreover, the government initiative in funding the isotope manufacturers is also expected to boost the market growth. The global nuclear medicine/radiopharmaceutical market is majorly comprised of five key players accounting for around 50% of the total market share. Key players include Covidien (), IBA Group, Lantheus Medical Imaging, Nordion, Triad Isotopes, Siemens Healthcare (PETNET Solutions), and NTP Radioisotopes. Acquisitions and mergers, new product launch, agreements and collaborations, and expansions were the main strategies followed by the key players in the global nuclear medicine market. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Global Nuclear Medicine Market By End-Users 5. Radiopharmaceuticals By Type 6. Stable Isotopes 7. Regional Market Analysis 8. Company Developments 9. Major Player Profiles - CIL - Cardinal Health, Inc. - GE Healthcare - IBA Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Mallinckrodt Plc - NTP Radioisotopes - Nordion Inc - Taiyo Nippon Sanso Corporation For more information visit http://www.researchandmarkets.com/research/n6gz6w/nuclear
CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020
M2 - Mon Nov 17, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/llklcc/global) has announced the addition of the "Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020" report to their offering. The nuclear medicine market by indication is segmented as oncology, cardiology, inflammation, nephrology, neurology, lymphology, thyroid glands, and gastro intestinal. Cardiology holds the largest share in 2013 in SPECT nuclear medicine market whereas nephrology is the fastest growing application of this segment. Increasing incidence of cardiac ailments, aging population, and preference for non invasive diagnostic procedures are driving the market for cardiology segment. Oncology contributes to the largest share of around $1 billion and is also the fastest growing segment in PET market with a CAGR of more than 7%. Nephrology is the fastest growing segment in the therapeutics. Increase in therapeutic application, public awareness, use of hybrid imaging, technological advancements, cyclotron production of radiopharmaceuticals, efficient diagnosis and treatments, emerging radioisotopes and replacement of traditional equipment are factors or opportunities expected to drive the nuclear medicine market. However, stringent regulatory issues, supply shortage, radio toxicity, high cost and huge investment are factors hindering the market growth during the forecasted period. North America holds the largest share for nuclear medicine market, followed by Europe. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. Asia-Pacific (APAC) and Rest of the World are poised to grow at a CAGR of more than 6% and 8% respectively by 2020. This region growth is attributed to aging population, rise in public awareness. Countries like China, India, Australia, and Brazil will be major contributors to the growth of the market. Reasons to Buy: - Nuclear medicine/Radiopharmaceuticals usage and demand by various end-users across the globe - Emerging isotopes as well as alternative isotopes for use both in the SPECT and PET segments - Emerging applications in Nuclear Medicine - Regulations and Reimbursement scenario - Stable isotopes study being a value addition - Competitive landscaping and Major player profiles Key Topics Covered: 1. Summary 2. Introduction 3. Market Overview 4. Global Radiopharmaceutical market, by End-User 5. Global Radiopharmaceutical market, by Application 6. Stable Isotopes 7. Geographic Analysis 8. Competitors Landscape 9. Major Company Profiles - CIL - Cardinal Health, Inc. - GE Healthcare - IBA Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Mallinckrodt Plc - NTP Radioisotopes - Nordion Inc - Taiyo Nippon Sanso Corporation For more information visit http://www.researchandmarkets.com/research/llklcc/global
CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Global Nuclear Medicine/Radiopharmaceuticals Global Market 2014-2020
M2 - Mon Sep 22, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jr579/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2020" report to their offering. The global nuclear medicine/radiopharmaceutical market is poised to reach around $6 billion by 2017 Nuclear medicine deals with the radioisotope applications in diagnosis and treatment of disease. Radiopharmaceuticals are drugs containing radionuclide's. Administration of radiopharmaceuticals facilitated to image bone, organs and the disease process in body at early stage based on cellular function and physiology. Around 200 radioisotopes are used regularly by the physicians for diagnosis and treatment across the globe. The global nuclear medicine/radiopharmaceutical market is segmented into diagnostic (SPECT and PET) and therapeutic areas (Beta, Alpha emitter, and Brachytherapy). Tc-99m and F-18 are proved to be the most dominant isotopes in SPECT and PET markets respectively. In addition, Rb-82 and Tl-201 are expected to register high growth in diagnostic market. Whereas Y-90 and Lu-177 are witnessing high growths in beta therapy radioisotopes market. Paediatrics, cardiology, oncology, neurology and psychiatry are some of the prominent applications areas of nuclear medicine. Increase in use of SPECT and PET scans, and awareness by physicians for treatment of coronary heart disease, Alzheimer's disease, breast cancer and bone metastasis are some of the major drivers of nuclear medicine market. Moreover, the growing therapeutic areas such as lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma also play a crucial role in the market growth. Whereas, the half-life of radiopharmaceuticals, high capital demand, lack of proper GMP (Good Manufacturing Practice), and inefficient effluent treatment are found to be the major factors hampering the nuclear medicine/radiopharmaceutical market growth. Increasing medical applications, rising demand in emerging economies and technological advancements in neurological applications are providing growth opportunities while, stringent regulatory guidelines and shutdown of nuclear reactors for radioisotope production are considered to be the major threats to the market growth. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Global Nuclear Medicine Market By End-Users 5. Radiopharmaceuticals By Type 6. Stable Isotopes 7. Regional Market Analysis 8. Company Developments 9. Major Player Profiles - CIL - Cardinal Health, Inc. - GE Healthcare - IBA Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Mallinckrodt Plc - NTP Radioisotopes - Nordion Inc - Taiyo Nippon Sanso Corporation For more information visit http://www.researchandmarkets.com/research/4jr579/nuclear
CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Asia-Pacific Nuclear Medicine Market - Trends And Forecasts 2014-2020
M2 - Thu Sep 18, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hvtnrb/asiapacific) has announced the addition of the "Asia-Pacific Nuclear Medicine Market - Trends And Forecasts (2014-2020)" report to their offering. Asia-pacific nuclear medicine market was valued at $480.5 million in 2012 and is expected to reach $853 million in 2019 with a healthy CAGR of 10.6% One of the popular forms of medical specialty, nuclear medicines involves application of radioactive substances in treatment of various diseases and disorders. Also known as, radiopharmaceuticals, these drugs contain radio-emitting ionization radiation and help in diagnosing disease and provide suitable treatment. Accurate identification and treatment of the disease are two major advantage of the nuclear medicine. Rising demand and evolving technology in the healthcare industry are the strongest driving factors for the global nuclear medicine market, which is aiming at steady growth in terms of revenue and global adoption. Increasing use of SPECT and PET technology for the treatment of the diseases propels market to grow further. Persistent side effects of cancer chemotherapy and radiation therapy are also the driving factors for the market. However, market is constrained by short half life of the radioisotopes which make them difficult to use. Asia-Pacific nuclear medicine market is segmented by Therapeutic market and Diagnostic market. Both these segments are further categorized based on the types of medicines, their applications and demands. Based on these segments, experts claim that the therapeutic market is mainly dominated by beta emitters for oncology applications. Diagnostic market on the other hand is dominated by radioisotopes such as SPECT and PET . Based on countries, market is segmented into India, China and Japan. Japan is the dominant market for diagnostic radioisotopes with almost 40% share and has around 1,600 gamma cameras. The total number of PET institutes in Japan has increased around 6-7 times in the last 10 years. Major players in the market are Covidien , IBA Group, Lantheus Medical Imaging, Triad Isotopes, Siemens Healthcare (PETNET Solutions), NTP Radioisotopes. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Market Dynamics 5. Asia-Pacific Nuclear Medicine Market Segmentation 6. Nuclear Medicine Market, By Type Of Products 7. Diagnostic Market, By Applications 8. Others 9. Competitive Landscape 10. Top Players In The Market Companies Featured: - Bracco Imaging S.P.A. - Cambridge Isotope Laboratories, Inc. - Cardinal Health, Inc - Covidien, Plc - Eczacibasi-Monrol - Fujifilm Holdings Corporation - GE Healthcare (Subsidiary Of General Electric Company) - Iba Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Nordion, Inc. For more information visit http://www.researchandmarkets.com/research/hv...siapacific
GE: 25.15 (+0.26), CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Europe Nuclear Medicine Market - Trends And Forecasts 2014-2020
M2 - Wed Sep 17, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkxb7b/europe_nuclear) has announced the addition of the "Europe Nuclear Medicine Market - Trends And Forecasts (2014-2020)" report to their offering. Europe market for nuclear medicine stood at $1.4 billion in 2014 and is expected to reach approximately $1.9 billion in 2019 with a CAGR of 7.2% Market for Technetium-99m is expected to increase owing to the rise in cases of cancer and cardiac ailments. Nuclear medicine has high potential for treatment of neurological diseases like Parkinson's, Alzheimer's and dementia. Practitioners prefer radiopharmaceuticals over conventional methods of treatments in neurological diseases. Study estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Market Dynamics 5. Europe Nuclear Medicine Market Segmentation 6. Nuclear Medicine Market, By Type Of Products 7. Diagnostic Market, By Application 8. Others 9. Competitive Landscape 10. Company Profiles - Bracco Imaging S.P.A. - Cambridge Isotope Laboratories, Inc. - Cardinal Health, Inc. - Covidien, Plc - Eczacibasi-Monrol - Fujifilm Holdings Corporation - Ge Healthcare (Subsidiary Of General Electric Company) - Iba Group - Institute Of Radioelement (IRE) - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Nordion, Inc. For more information visit http://www.researchandmarkets.com/research/vk...pe_nuclear
GE: 25.15 (+0.26), CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Global Nuclear Medicine Market - Growth, Trends & Forecasts 2014-2019
M2 - Tue Sep 09, 8:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9krpdg/global_nuclear) has announced the addition of the "Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019)" report to their offering. Nuclear medicine market is estimated to reach US$1.69 Billion by 2015 Radiopharmaceuticals/ Nuclear are drugs that contain radionuclide-emitting ionization radiation, used in the nuclear imaging field to diagnose and treat diseases. Increasing incidences of cancer and cardiac ailments, Increasing awareness for radiopharmaceuticals, and ready availability of radiopharmaceuticals are the major driving forces for this market. Furthermore, increased public awareness and use of SPECT and PET also fuels the market growth. Growth in this market will be driven by new technology and varied uses of the technology. The major constrains for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Global Markets: Segmentation By Diagnostics 5. Global Markets: Segmentation By Therapeutics 6. Global Markets: Segmentation By Application 7. Global Markets:Segmentation By Geography 8. Competitive Landscape 9. Top Players In The Market 10. Company Profiles - Australian Nuclear Association And Technology Organization (Ansto) - Board Of Radiation And Isotope Technology (Brit) - Bracco Imaging S.P.A. - Cambridge Isotope Laboratories, Inc. - Cardinal Health, Inc. - Covidien, Plc - Eczacibasi-Monrol - Fujifilm Holdings Corporation - Ge Healthcare (Subsidiary Of General Electric Company) - Iba Group - Institute Of Atomic Energy Polatom Radioisotope Centre - Institute Of Isotopes Co., Ltd. - Institute Of Radioelement (IRE) - Institutes - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Nordion, Inc. - Ntp Radioisotopes (PTY), Ltd. - Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.) - Rotem Industries, Ltd., Inc. - Taiyo Nippon Sanso Corporation - Urenco Limited For more information visit http://www.researchandmarkets.com/research/9k...al_nuclear
GE: 25.15 (+0.26), CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Nordion's outstanding common shares acquired by Sterigenics International
M2 - Thu Aug 07, 7:18AM CDT
Nordion (TSX:NDN.TO) (NYSE:NDZ) revealed on Wednesday that it has acquired all of the outstanding common shares of Nordion by an affiliate of Sterigenics International under a plan of arrangement.
NDZ: 12.99 (-0.01)
Sterigenics International Completes $826 Million Acquisition of Nordion Inc.
Business Wire - Wed Aug 06, 1:01PM CDT
Sterigenics International LLC, the leading global provider of outsourced contract sterilization services and a portfolio company of GTCR, today announced it has completed its $826 million acquisition of Nordion Inc. (TSX:NDN) (NYSE:NDZ).
NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01)
Nordion Announces Completion of Acquisition by Sterigenics International
Business Wire - Wed Aug 06, 12:56PM CDT
Nordion Inc. (TSX:NDN) (NYSE:NDZ), a leading provider of products and services to the global health science market, announced today the successful completion of the previously announced plan of arrangement (the "Arrangement"
and all of the outstanding common shares of Nordion have been acquired by an affiliate of Sterigenics International LLC ("Sterigenics" . Pursuant to the Arrangement, the former holders of Nordion common shares will receive US$13.00 in cash in exchange for each common share held. NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01)
NYSE stocks posting largest volume decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
BRT: 6.98 (-0.02), MOG.B: 74.29 (+1.81), MOG.A: 74.61 (+1.47), FCE.A: 25.32 (-0.08), STZ: 113.03 (-0.48), NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01), BOXC: 23.30 (-0.53), STZ.B: 112.58 (-0.82)
Nordion Receives Investment Canada Act Approval and Announces Expected Closing Date for Acquisition by Sterigenics
Business Wire - Fri Aug 01, 4:00PM CDT
Nordion Inc. (TSX:NDN) (NYSE:NDZ) announced today that the Minister of Industry has approved the previously announced proposed acquisition of all the common shares of Nordion Inc. by Sterigenics, pursuant to the terms of the Investment Canada Act. This approval was the last regulatory approval required for the proposed acquisition.
NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01)
Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2019
M2 - Mon Jul 21, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx9c82/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Global market - Forecast to 2019" report to their offering. The global nuclear medicine/radiopharmaceutical market is poised to reach around $6 billion by 2017 at a CAGR of more than 7% The largest share in the global radiopharmaceuticals market is accounted by North America. Besides U.S. market Asia-Pacific region is also poised to show a remarkable growth. The Asia-Pacific radiopharmaceutical market is poised to reach approximately 14% by 2017 at a CAGR of around 11%. Countries such as China, India, Japan, South Korea, Brazil and South Africa possess reactors and other production units for isotopes. Moreover, the government initiative in funding the isotope manufacturers is also expected to boost the market growth. The global nuclear medicine/radiopharmaceutical market is majorly comprised of five key players accounting for around 50% of the total market share. Key players include Covidien (), IBA Group, Lantheus Medical Imaging, Nordion, Triad Isotopes, Siemens Healthcare (PETNET Solutions), and NTP Radioisotopes. Acquisitions and mergers, new product launch, agreements and collaborations, and expansions were the main strategies followed by the key players in the global nuclear medicine market. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Global Radiopharmaceutical market, by End-User 5. Global Radiopharmaceutical market, by Application 6. Stable Isotopes 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - CIL - Cardinal Health, Inc. - GE Healthcare - IBA Group - Isotec, Inc. (Sigma-Aldrich) - Lantheus Medical Imaging, Inc. - Mallinckrodt Plc - NTP Radioisotopes - Nordion Inc - Taiyo Nippon Sanso Corporation For more information visit http://www.researchandmarkets.com/research/wx9c82/nuclear
CAH: 86.08 (+0.04), NDZ: 12.99 (-0.01)
Nordion announces waiting period under HSR Act terminated for proposed acquisition by Sterigenics
M2 - Mon Jul 14, 6:12AM CDT
Health science company Nordion Inc (TSX:NDN) (NYSE:NDZ) announced on Friday the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act0, as amended, on 10 July 2014 by the Federal Trade Commission with respect to Sterigenics' proposed acquisition of Nordion.
NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01)
Lorillard and Fastenal are big market movers
AP - Fri Jul 11, 3:59PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
ZUMZ: 38.84 (+0.14), RAI: 71.86 (-1.23), AMZN: 381.83 (+4.66), LO: 67.30 (-0.80), CRAY: 32.65 (+0.24), UAL: 66.23 (-1.11), RCII: 30.49 (+0.92), FAST: 42.50 (+0.26), AMRE: 26.51 (unch), EBAY: 56.47 (+1.73), ECOM: 9.69 (+0.63), SRPT: 12.76 (+0.11), REG: 66.77 (-0.46), NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01), CBS.A: 60.82 (+1.76), MTG: 9.18 (+0.07), CBS: 59.83 (+2.06)
NYSE stocks posting largest percentage increases
AP - Fri Jul 11, 12:38PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at 1 p.m.:
FSM: 4.56 (+0.03), FVI.TO: 5.67 (+0.02), EDR.TO: 3.08 (+0.10), TCI: 10.67 (-0.13), GPRK: 4.35 (+0.17), ECOM: 9.69 (+0.63), LO: 67.30 (-0.80), HGT: 8.10 (+0.02), NDN.TO: 14.36 (+0.16), NDZ: 12.99 (-0.01), EXK: 2.48 (+0.08)
